Haizheng Pharmaceutical (600267.SH): HS387 tablets obtained US FDA clinical trial approval notice for new drugs

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. Recently, the company received a notice from the US Food and Drug Administration (“US FDA”) that the clinical trial application for HS387 tablets declared by the company has been approved by the US FDA, and clinical trials can be carried out in the US. HS387 tablets are selective KIF18A inhibitors independently developed by the company. They are intended for the treatment of advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer.